Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447531 · ClinicalTrials.gov registry record · NA
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
A NA study of Malignant Glioma, sponsored by John M. Buatti.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07447531: Recruiting NA study of Malignant Glioma, sponsored by John M. Buatti.
NCT07447531 is a NA study of Malignant Glioma that is actively recruiting participants, run by John M. Buatti. The registered enrollment target is 15 participants, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07447531, a NA study of Malignant Glioma, is actively recruiting participants, sponsored by John M. Buatti.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
Primary Outcome
Will be characterized with mixed effects regression modeling. Correlation between the two biomarkers will be estimated with the multivariate linear mixed effects regression approach of Hamlett, Ryan, and Wolfinger. Cluster bootstrapping will be employed to calculate a 95% confidence interval for their correlation and a p-value for testing its significance at the 5% level.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE T2 (Observed)-Weighted Imaging
Study Locations (1)
Iowa
- University of Iowa Health Care - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2028-10-06 |
| Phase | NA |
What NCT07447531 shows while recruiting
NCT07447531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT07447531 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT07447531 about?
NCT07447531 is a clinical study titled "T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas". This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
What is the current status of trial NCT07447531?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-10-03. Estimated completion is 2028-10-06.
What conditions does trial NCT07447531 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT07447531?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), T2 (Observed)-Weighted Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT07447531?
This trial is sponsored by John M. Buatti, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07447531 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07447531's enrollment target sits among peer trials
15 39th of 40 the lowest of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
ACTIVE NOT RECRUITING · NA
-
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
COMPLETED · NA
-
Mapping of Electrical Properties in the Brain
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI